XML 48 R38.htm IDEA: XBRL DOCUMENT
v3.5.0.2

Fair Value Measurements (Acquisition of CyDex) (Details) - Cydex Pharmaceuticals, Inc - USD ($) $ in Millions | 6 Months Ended | 12 Months Ended
--- | --- | ---
Jun. 30, 2016 | Dec. 31, 2015
Credit Derivatives [Line Items] |  |
Amount Of Revenue For Contingent Consideration | $ 15.0 |
Contingent Consideration Classified as Equity |  |
Credit Derivatives [Line Items] |  |
Range of annual revenue subject to revenue sharing | $ 24.2 | $ 22.5
Revenue volatility | 25.00% | 25.00%
Average of probability of commercialization | 82.00% | 73.00%
Sales beta | 0.30 | 0.40
Credit rating | BB | BB
Equity risk premium | 6.00% | 6.00%

X
- Definition Amount of revenue for contingent consideration. + References No definition available. + Details
Name: | lgnd_AmountOfRevenueForContingentConsideration
Namespace Prefix: | lgnd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Fair Value Inputs, Annual Revenue Subject To Revenue Sharing + References No definition available. + Details
Name: | lgnd_FairValueInputsAnnualRevenueSubjectToRevenueSharing
Namespace Prefix: | lgnd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Average Probability of Commercialization + References No definition available. + Details
Name: | lgnd_FairValueInputsAverageOfProbabilityOfCommercialization
Namespace Prefix: | lgnd_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair Value Inputs, Credit Rating + References No definition available. + Details
Name: | lgnd_FairValueInputsCreditRating
Namespace Prefix: | lgnd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair Value Inputs, Sales Beta + References No definition available. + Details
Name: | lgnd_FairValueInputsSalesBeta
Namespace Prefix: | lgnd_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CreditDerivativesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb) -URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueAssumptionsExpectedVolatilityRate
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage above fair value that an investor seeking to acquire control of an entity will pay, used as an input to measure fair value. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb) -URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueInputsControlPremium
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lgnd_CydexPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByLiabilityClassAxis=us-gaap_ContingentConsiderationClassifiedAsEquityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |